Download : Ochoa, Augusto C. BIOGRAPHICAL SKETCH

Program Director/Principal Investigator (Last, First, Middle):
Ochoa, Augusto C.
BIOGRAPHICAL SKETCH
Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. DO NOT EXCEED FOUR PAGES.
NAME
POSITION TITLE
Glenn Morris Mills, MD
Professor of Medicine
MB-CCOP Principal Investigator
eRA COMMONS USER NAME (credential, e.g., agency login)
gmmills
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and
residency training if applicable.)
DEGREE
INSTITUTION AND LOCATION
MM/YY
FIELD OF STUDY
(if applicable)
Millsaps College, Jackson, Mississippi
University of Mississippi Medical Center,
Jackson, MS
05/71
Chemistry
MD
12/74
Internal Medicine
Tripler Army Medical Center, Honolulu, Hawaii
Postdoctor
al
06/76
Internal Medicine
Brooke Army Medical Center, Fort Sam
Houston, TX
Fellowship
06/80
Hematology/Oncolog
y
A. Personal Statement
As Director of the Feist-Weiller Cancer Center, Professor and Vice Chairman of the Department of Medicine,
Chief of Hematology and Medical Oncology, Director of Clinical Research and Program Director of the
Hematology and Medical Oncology fellowship program at LSU Health Sciences Center – Shreveport
(LSUHSC-S), I feel I am uniquely qualified to sit on the executive committee and be a site leader for our
Shreveport component and sub-components for the Gulf South-Minority Based NCORP (GS-MB-NCORP).
The overall goal of the GS-MB-NCORP is to decrease cancer incidence and deaths among the minorities
throughout the state of Louisiana through participation in clinical research trials with an emphasis on cancer
control and prevention. I have the expertise and experience in clinical research to aide in achieving the goals
of the GS-MB-NCORP. I have been the LSUHSC-Shreveport MBCCOP Principal Investigator since the
inception of the program in 2007. I have been the SWOG Principal Investigator for LSUSHC-Shreveport since
1986, and our site has received recognition from SWOG as a top accruing minority site as well as for the
quality of our data. I have been a member of the Hematology/Oncology faculty at LSUHSC-S since 1986 and
Director of Clinical Research at Feist Weiller Cancer Center since 2001. Under my direction and the support
and participation of medical hematologist/oncologists, we have been successful in building a clinical research
program dedicated to patient enrollment and strict compliance with federal regulatory guidelines. Successful
collaboration with a comprehensive multi-disciplinary group of specialists who assist in identifying enrolling,
and treating study patients is a major part of the strength and success of our program. I maintain strong ties
with other oncologists and physicians in the community, as well as throughout the state, including Dr. Augusto
Ochoa. As well, through regular attendance at cooperative group, NCI CCOP, and research base meetings, I
have developed good relationships and channels of communication with the leaders in the NCORP program. I
feel that by joining forces with the LSUHSC-New Orleans MB-CCOP as well as the Mary Bird Perkins NCI
Community Cancer Center Program, we can drastically increase enrollments of our patient population into NCI
clinical trials.
B. Positions and Honors
Positions and Employment
1986-1992
Assistant Professor of Medicine, Section of Hematology/Oncology, LSU School of
Medicine, Shreveport, Louisiana
1989–1992
Director, Hematology/Oncology Fellowship Program Feist-Weiller Cancer Center,
LSU School of Medicine-Shreveport
7/1992-6/2000
Associate Professor of Medicine, Section of Hematology/Oncology, LSU Health
Sciences Center, Shreveport, Louisiana July 1992 – June 2000
PHS 398/2590 (Rev. 06/09)
Page
86
Biographical Sketch Format Page
Program Director/Principal Investigator (Last, First, Middle):
7/1999-1/2000
7/1999–1/2000
1997 to 2011
1988 – Present
7/2000-Present
4/2001–Present
1995 – 2012
2012 – Present
Ochoa, Augusto C.
Acting Chief, Hematology/Oncology Section, LSU Health Sciences Center,
Shreveport, Louisiana
Director, Hematology/Oncology Fellowship Program Feist-Weiller Cancer Center,
LSU School of Medicine-Shreveport
Associate Director, Feist-Weiller Cancer Center LSU Health Sciences Center,
Shreveport, Louisiana
Consultant, Hematology/Oncology Service, Overton Brooks VA Medical Center,
Shreveport, LA 71101
Professor of Medicine, Section of Hematology/Oncology, LSUHSC-Shreveport,
Shreveport, Louisiana
Vice Chairman, Department of Medicine LSUHSC-Shreveport, Shreveport,
Louisiana
Director of Clinical Research, Feist-Weiller Cancer Center LSUHSC-Shreveport
Director, Feist-Weiller Cancer Center LSU Health Sciences Center,
Shreveport, Louisiana
Other Experience and Professional Memberships
AOA, 1974 - Present
Assistant Investigator, Polycythemia Vera Study Group, New York, New York, 1980 - 1981
Southwest Oncology Group, Principal Investigator 1980 – Present
SWOG Committee Memberships:
Leukemia Committee, 1980 – Present
Leukemia Pathology Review, 1988 - Present
Lung Committee, 1986 - Present
Quality Assurance Auditor 1982 – Present
GI Committee, 1998 to present
Head and Neck Committee, 1998 to 2006.
Cancer Control Committee, 1998 to present
Lymphoma Committee, 1985 – 2002
Member, American Association for the Advancement of Science, 1980 - Present
Member, American Society of Hematology, 1981 - Present
Member, American Federation for Clinical Research 1981 - Present
President, San Antonio Blood Club, 1985
Member, American Society of Clinical Oncology, 1986 - Present
Member, Southern Medical Association, 1988 - Present
Member, Southern Oncology Association, 1988 - Present
Member, Louisiana State Medical Society, 1992 – Present
Member, Caddo Parish Medical Society, 1992 – Present
Member AMA, 1992 to present.
Member, Association of Program Directors in Internal Medicine, 1992-1997
Member, American Association of Cancer Research, 1994-Present
Member, Association of Patient Oriented Research, 2000
Member, Association of Subspecialty Professors of Medicine, 1999 to present.
Member, International Society of Lung Cancer, 1999 to present.
Member Association of Community Cancer Centers, 1999 to present.
Member NCI Clinical Trials Support Unit, 2000
Member ACGME Residency Review Committee in Internal Medicine Appointed 1/1/2003-present;
Executive Committee 2004 - present
Member, Coalition For a Tobacco Free Louisiana, 2002 to present
Medical Director, Northwest Louisiana Tumor Registry, 1987 – 1988 & 1999 to 2001
Member, Louisiana State Hemophilia Advisory Committee, 1989 - 1992
Board of Directors, Northwest Louisiana Chapter of the American Cancer Society, 1990 - 1992
Member, Louisiana Lung and Cancer Trust Fund Board, 1990 - 1995
Treasurer, Louisiana Lung and Cancer Trust Fund Board, 1992 - 1995
Grant Review Committee for LSUMC-NO Center for Excellence in Cancer, 1995
PHS 398/2590 (Rev. 06/09)
Page
87
Continuation Format Page
Program Director/Principal Investigator (Last, First, Middle):
Ochoa, Augusto C.
C. Selected Peer-reviewed Publications
1. Adelstein DJ, Moon J, Hanna E, Giri PG, Mills GM, Wolf GT, Urba SG. Docetaxel, cisplatin, and
fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation
and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest
Oncology Group phase II trial (S0216). Head Neck. 2010 Feb;32(2):221-8.
2. Sequist LV, Fidias PM, Temel JS, Kolevska T, Rabin MS, Boccia RV, Burris HA, Belt RJ, Huberman
MS, Melnyk O, Mills GM, Englund CW, Caldwell DC, Keck JG, Meng L, Jones M, Brown GL, Edelman
MJ, Lynch TJ. Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with
carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer. J
Thorac Oncol. 2009 Nov;4(11):1389-96.
3. Ampil F, Sangster G, Mills G, Nathan CO, Lian T, Hall A. Radiologic findings after successful
chemoradiation for nasopharyngeal cancer with skull base erosion. Ear Nose Throat J. 2010
Jan;89(1):38-41.
4. Ekshyyan O, Mills GM, Lian T, Amirghahari N, Rong X, Lowery-Nordberg M, Abreo F, Veillon DM,
Caldito G, Speicher L, Glass J, Nathan CO. Pharmacodynamic evaluation of temsirolimus in patients
with newly diagnosed advanced-stage head and neck squamous cell carcinoma. Head Neck. 2010
Dec;32(12):1619-28.
5. Peddi P, Slay LE, Lilien DL, Fowler MR, Cotelingam J, Veillon DM, Ayirookuzhi S, Koshy N, Mills GM,
Munker R. Metastatic malignant melanoma in a patient with Hodgkin's lymphoma in remission. J La
State Med Soc. 2010 Jan-Feb;162(1):47-50.
6. Chu DZ, Hussey MA, Alberts DS, Meyskens FL Jr, Fenoglio-Preiser CM, Rivkin SE, Mills GM, Giguere
JK, Blanke CD, Goodman GE. Colorectal Chemoprevention Pilot Study (SWOG-9041), randomized
and placebo controlled: the importance of multiple luminal lesions. Clin Colorectal Cancer. 2011
Dec;10(4):310-6.
7. Armaghany T, Wilson JD, Chu Q, Mills G. Genetic alterations in colorectal cancer. Gastrointest Cancer
Res. 2012 Jan;5(1):19-27. PMC3348713.
8. Ampil FL, Caldito G, Mills G, Marion J, Balandin A, Ponugupati J. Short survival after palliative
radiotherapy for brain metastases in lung cancer: does the end justify the means? Am J Hosp Palliat
Care. 2013 Jun;30(4):331-3.
9. Ampil F, Caldito G, Mills G, Takalkar A, Ghali G, Kim D. Chemoradiotherapy for unresectable stage
IVB head and neck cancer. J La State Med Soc. 2012 Sep-Oct;164(5):260-4.
10. Jafri SH, Mills G. Lifestyle modification in colorectal cancer patients: an integrative oncology approach.
Future Oncol. 2013 Feb;9(2):207-18.
11. Ampil F, Chaudhery S, Devarakonda S, Mills G. Extended survival after chemotherapy and
conservative radiotherapy for HPV-16 positive stage IVB oropharyngeal carcinoma. Acta Oncol. 2013
Aug;52(6):1236-7.
12. Jafri SH, Shi R, Mills G. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic
marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review. BMC
Cancer. 2013 Mar 27;13:158. PMC3618002.
13. Eberhardt WE, Mitchell P, Schiller JH, Brown MP, Thomas M, Mills G, Jehl V, Urva SR, De Leo JJ,
Gogov S, Papadimitrakopoulou V. Feasibility of adding everolimus to carboplatin and paclitaxel, with or
without bevacizumab, for treatment-naive, advanced non-small cell lung cancer. Invest New Drugs.
2013 Apr 12. [Epub ahead of print]
14. Shi R, Mills G, McLarty J, Burton G, Shi Z, Glass J. Commercial insurance triples chances of breast
cancer survival in a public hospital. Breast J. 2013 Nov-Dec;19(6):664-7. [PubMed - in process]
15. Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl
BS, Miller TP, Tubbs RR, Marcellus D, Friedberg JW, Barton KP, Mills GM, LeBlanc M, Rimsza LM,
PHS 398/2590 (Rev. 06/09)
Page
88
Continuation Format Page
Program Director/Principal Investigator (Last, First, Middle):
Ochoa, Augusto C.
Forman SJ, Fisher RI. Autologous transplantation as consolidation for aggressive non-Hodgkin's
lymphoma. N Engl J Med. 2013 Oct 31;369(18):1681-90.
D. Research Support
GLENN M. MILLS, MD
ACTIVE
U10CA128567
08/01/2007-05/31/2015
NIH-NCI
LSUHSC-Shreveport Feist Weiller Cancer Center MBCCOP
The Feist-Weiller Cancer Center (FWCC) Minority-Based Community Clinical Oncology Program (MB-CCOP)
aims to provide increased access to state-of-the-art cancer prevention care, and control through NCIsponsored clinical trials to the minority and indigent populations in the northwestern section of La., and
throughout the state of Louisiana.
Role: Principal Investigator
Cephalon – Protocol #C18083/3064/NL/MN
08/2009 – 03/2017
CEPHALON Oncology
An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and Rituximab (BR)
Compared With Rituximab, Cuyclopyosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab,
Cyclosphosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in the First-Line Treatment of
Patients with Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)
The major goal of this project is to compare the complete response rate of bendamustine and rituximab
with that of standard treatment regimens of either rituximab, cyclophosphamide, vincristine and prednisone,
or rituximab, cyclosphosphamide, doxorubicin, vincristine, and prednisone in the first-line treatment of
patients with advanced indolent NHL or mantle cell lymphoma on the basis of a non-inferiority margin of
15%.
Panorama 1 – Protocol #CLBH589D2308
12/2009 – 06/2014
NOVARTIS
A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Panobinostat in
Combination with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma.
It is the purpose of this study to compare treatment with BTZ/Dex + PAN to BTZ/Dex + Placebo in patients
with previously treatment MM whose disease has recurred or progressed. Progression free survival is the
primary endpoint of the study.
Completed Research Support
Wyeth 3066KI-404-WW
02/25/2008 – 03/01/2012
WYETH Pharmaceuticals
“A Randomized Trial of Temsirolimus and Sorafenib as Second-Line Therapy in Patients with Advanced
Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy”
The major goals of this project are to compare the efficacy, safety and tolerability of temsirolimus and
sorafenib when used as single agents in the second-line setting in subjects with advanced RCC who have
failed first-line treatment with sunitinib.
Amgen 20062088
11/26/2007 – 12/01/2012
AMGEN Pharmaceutical Co.
“Phase II, Single-Arm, Open-Label, Multi-center Trial of Second-Line Panitumumab Monotherapy in
Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck”
The major goal of this project is to estimate the effect of second-line panitumumab monotherapy on
objective response rate in patients with metastatic or recurrent squamous cell carcinoma of the head and
PHS 398/2590 (Rev. 06/09)
Page
89
Continuation Format Page
Program Director/Principal Investigator (Last, First, Middle):
Ochoa, Augusto C.
neck. Time to response, duration of response, rate of disease control, time to progression, PFS, and OS
will also be assessed.
PHS 398/2590 (Rev. 06/09)
Page
90
Continuation Format Page